Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00418704
Status:
COMPLETED
Last Update Posted:
2013-10-01
First Post:
2007-01-04
Brief Title:
Elderly Independent Patients With Non Small Cell Lung Cancer NSCLC
Sponsor:
Groupe Francais De Pneumo-Cancerologie
Organization:
Groupe Francais De Pneumo-Cancerologie
Study Overview
Official Title:
A Multicenter Randomized Phase II Trial in NSCLC Stage IV and IIIB T4 With Pleural Effusion in Elderly Independent Patients the Schedule Docetaxel Gemcitabine First Line Following by Erlotinib When Progression Versus Erlotinib First Line Following by Gemcitabine When Progression
Status:
COMPLETED
Status Verified Date:
2013-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine duration before progression of first-line treatment chemotherapy following erlotinib in second-line comparing erlotinib in first-line following chemotherapy in second-line in old patients with none small cell lung cancer
Detailed Description:
A multicenter phase II trial prospective randomized open non comparative
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None